Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Citric acid + potassium citrate + sodium citrate is a systemic urinary alkalizing agent composed of citric acid and its potassium and sodium salts. It is primarily indicated for the treatment of metabolic acidosis and the management of kidney stones (specifically calcium oxalate and uric acid stones) associated with hypocitraturia. Upon oral administration, the citrate salts are metabolized to bicarbonate, which increases systemic and urinary pH. This alkalinization helps dissolve uric acid stones and prevents the crystallization of calcium salts. Additionally, increased urinary citrate levels form chemical complexes with calcium, reducing the concentration of free calcium available for stone formation. The drug is also used as an adjuvant in gout therapy to facilitate the excretion of uric acid. It is commonly available as an oral liquid solution.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on citric acid + potassium citrate + sodium citrate.